Drug-coated balloon-based versus drug-eluting stent-only revascularization in patients with diabetes and multivessel coronary artery disease
Authors' conclusion
In multivessel CAD, the clinical benefit of a DCB-based revascularization strategy appears to be more evident in patients with DM than in those without DM after 2 years of follow-up.
Study context
- Population
- Patients with multivessel coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), with or without diabetes mellitus (DM) (104 with DM in drug-coated balloon (DCB)-based group)propensity-matched
- Participants
- 254 vs 254
- Exposure
- DCB-based vs drug-eluting stent (DES)-only revascularization
- DCB-basedn = 254
- DES-onlyn = 254reference
- Outcome
- Major adverse cardiovascular events (MACE): cardiac death, MI, stroke, stent or target lesion thrombosis, target vessel revascularization and major bleeding
- Follow-up
- 2 years
Methodological detailsregistry comparator (PTRG-DES)
- Registry comparator (PTRG-DES)
Main finding
As reported in the abstract
MACE by DM status (subgroups)
DCB-based vs DES-onlyHazard ratio (95% CI)P value
Patients with DM
0.19(0.05–0.68)
P = 0.003Patients without DM
0.52(0.20–1.38)
P = 0.167Observational data: associations, not effects.
Further findings
Cardiac death
- Lower risk with DCB-based vs DES-only in DM; not in those without DM
Burden of DES and small DES (<2.5 mm) used
- Lower with DCB-based vs DES-only in patients with and without DM
Original publication
Drug-coated balloon-based versus drug-eluting stent-only revascularization in patients with diabetes and multivessel coronary artery disease. Cardiovasc Diabetol. Published 20 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →